2 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Unknown 2 |
| Phase 2 | 2 | Unknown 2 |
Follow Effects of Immunotherapy: new trials by email Literature Review of Effects of Immunotherapy trials Research Report on Effects of Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TIL and Anti-PD1 in Metastatic Melanoma Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha - Toxicity, Drug, Adverse Drug Event | Phase 1 / Phase 2 | Unknown | Leiden University | 34 | 2018-07-31 | 2023-12-12 |
| Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) - Acute Myelogenous Leukemia, Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Jules Bordet Institute | 20 | 2011-12-01 | 2012-01-20 |
Drug-Related Side Effects and Adverse Reactions (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Chemically-Induced Disorders (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1) · Skin Neoplasms (1)
Nivolumab (1)
Jules Bordet Institute (1) · Leiden University (1)
Belgium (1) · Netherlands (1)
Ellen Kapiteijn, Dr. (1) · Philippe Martiat, MD PhD (1)